New 4-year study shows that lutein supplementation at 12 mg/day may provide up to 10 years protection against further loss of sight for patients with Retinitis Pigmentosa


n Monday, April 12, 2010, a breakthrough new study was published online in the Archives of Ophthalmology that offers new hope for the prevention of visual field loss in patients suffering from retinitis pigmentosa.

In this randomized, placebo-controlled, double-blind study conducted by lead author Eliot Berson, M.D. (Berman-Gund Laboratory at Harvard Medical School), two hundred and twenty-five non-smoking patients aged 18-60 years with retinitis pigmentosa (RP) received either 12 mg of FloraGLO® lutein or a placebo tablet daily. All patients received 15,000 IU/day of vitamin A and throughout the study period were advised to eat 1 to 2 servings of oily fish per week to increase their intake of long chain omega-3 polyunsaturated fatty acids (PUFA). During the 4 years of supplementation, a decline in visual field area was apparent in all patients. However, a significantly lower decline was observed in the group supplemented with 12 mg/day lutein, compared to the placebo group. The overall decline in combined central and midperipheral visual fields was slowest in patients with the highest serum lutein levels or with the highest increase in macular pigment optical density (MPOD). The authors estimated that the benefit of lutein supplementation on the long-term course of midperipheral visual field among RP patients also taking vitamin A and eating an oily fish diet would be 3 to 10 years of protection against further loss of sight. No adverse effects of lutein supplementation were noted during the 4 years of supplementation.

Retinitis pigmentosa is the name of a group of inherited eye diseases which results in poor night vision in adolescence, and the loss of side (midperipheral and far peripheral) vision in adulthood with tunnel vision as the outcome. As this disease progresses, patients loose their central vision by 60 years of age. Retinitis pigmentosa has a prevalence of 1 in 4,000 people and an estimated 50,000 to 100,000 people are affected in the United States.

For this study, DSM Nutritional Products supplied the lutein tablets which contained FloraGLO Lutein and used the Actilease®, technology in order to increase the bioavailability of lutein.

About DSM Nutritional Products

DSM Nutritional Products is the world’s leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries. The business has sales of over EUR 2 billion and a long tradition as a pioneer in the discovery of new products, new formulations and attractive applications for all industry segments. More information at

DSM – the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM’s products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM has annual net sales of about EUR 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information:

Kemin and DSM Strategic Alliance

In 2008, Kemin and DSM joined forces working under an exclusive strategic alliance. Kemin supplies FloraGLO brand lutein ( exclusively through DSM, and DSM globally commercializes FloraGLO brand lutein products through distributors and directly to customers. Customers and consumers benefit from the synergies achieved by the collaboration through DSM’s global reach, unique formulation technology and broad product portfolio when combined with Kemin’s lutein knowledge, intellectual property, technical know-how and market development expertise. For more information about Kemin, visit